Navigation Links
Axial Biotech Appoints Retired Roche Diagnostics Executive to Board
Date:10/14/2008

Experienced leader will provide commercialization expertise to company

SALT LAKE CITY, Oct. 14 /PRNewswire/ -- Axial Biotech, Inc., a company revolutionizing spine care through the development of molecular diagnostic technologies, announced today the appointment of William L. Lister as the newest member of the Board of Directors. Lister will serve on the board's Compensation Committee and will focus on guiding the company in the commercialization of new molecular assays.

"I am excited about Axial Biotech's potential to dramatically change the detection and treatment of many spinal disorders. The Company's first product, called ScoliScore(TM), is a prognostic assay that will identify the likelihood for spinal curve progression," stated Lister. "This product has the opportunity to greatly benefit children diagnosed with this crippling disease."

"The company is very pleased to have Bill join our board as a director," said John Climaco, Axial Biotech's President & CEO. "Bill has a very impressive record in the diagnostics industry of creating and executing major strategies as well as helping companies build the foundation for meaningful and sustained growth. His skills will be instrumental in helping the company achieve its new expansion imperatives."

Lister has had a distinguished career in sales, marketing and several management positions in the healthcare sector with companies focused in the diagnostic and pharmaceutical industries. Most recently, Lister was the Senior Vice President and General Manager of Patient Care at Roche Diagnostics Corporation. In this position, Lister was responsible for the U.S. Diabetes Monitoring, Insulin Pump and Point of Care Diagnostics, along with the Global Drugs of Abuse Business Unit. He was a member of the Corporation's Management Group, which was responsible for setting policy and overseeing all U.S. diagnostic and biochemical operations along with the Global Diabetes Care Operating Committee. In 2001, he was selected as the first recipient of Roche Diagnostics Corporation's Leadership Award. Upon his retirement in 2004, Roche Diagnostics created the William L. Lister Award to be presented annually at their national sales meeting.

Prior to Roche, Lister spent 10 years with Boehringer Mannheim Corporation where he held various general management and senior level sales and marketing positions in the Diagnostics and Biochemical Divisions. From 1973 to 1986, Lister worked for Eli Lilly and Company in a number of sales and marketing positions, including Director of Market Research for the Pharmaceutical Division.

Lister received a Bachelor of Science degree in Management and a Master of Science degree in Marketing from Indiana State University in 1966 and 1967 respectively. In 2001, he was recognized by the University's College of Business as its Outstanding Alumnus. In addition, he received Indiana State University's Distinguished Alumni Award in 2005.

About Axial Biotech

Axial Biotech, Inc. develops molecular diagnostic assays and other technologies for common spinal diseases and disorders. Axial has developed the first DNA based prognostic test for Adolescent Idiopathic Scoliosis. Axial is accredited by the College of American Pathologists (CAP) and is certified to comply with the Clinical Laboratory Improvement Amendments (CLIA). Founded in 2002, Axial is based in Salt Lake City, Utah.


'/>"/>
SOURCE Axial Biotech, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Axial Biotech Meets Major Scientific Milestones; Receives $6 Million Tranche of Series B Financing
2. Axial Biotech Names New VP of Reimbursement and Regulatory Affairs
3. Axial Biotech appoints new Vice President of Strategic Initiatives
4. Spherix Shareholders Support Companys Focus on Naturlose, Biotechnology
5. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
6. ISI Increases West Coast Life Science and Biotech Support for Emerging Companies with Expansion in San Francisco and San Diego
7. Amyris Biotechnologies Co-Founder Neil Renninger Named to Technology Reviews Prestigious TR35 List of Top Young Innovators
8. Finkelstein Thompson LLP Announces GPC Biotech AG Investigation
9. Operon Biotechnologies and DNA2.0 Announce Co-Marketing and Technology Development Partnership
10. Clinical Data Acquires Epidauros Biotechnologie AG, Significantly Enhancing Proprietary Genetic Biomarker Portfolio
11. Microchip Biotechnologies, Inc. Secures Exclusive License to Use New University of Alberta Technology for Developing Microfluidic Devices
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... (PRWEB) , ... December 08, 2016 , ... ... the FrontPanel SDK that provide essential device-to-computer interconnect using USB or PCI Express, ... require FrontPanel support. The FOMD-ACV-A4 is a small, thin, SODIMM-style module that fits ...
(Date:12/8/2016)... ... December 08, 2016 , ... KBioBox llc ... to client demand KbioBox developed a sophisticated “3 click” gene dditing off target ... from KBioBox’s new website, https://www.kbiobox.com/ and powered by the company’s ...
(Date:12/8/2016)... 8, 2016  Soligenix, Inc. (OTCQB: SNGX) (Soligenix ... on developing and commercializing products to treat rare ... announced today the long-term follow-up data from its ... first-in-class Innate Defense Regulator (IDR), in the treatment ... cancer patients undergoing chemoradiation therapy (CRT).  The additional ...
(Date:12/8/2016)... Korea , Dec. 8, 2016 Eutilex ... $21 billion KRW (US $18.9M) Series A financing. This ... Investment, G.N. Tech Venture and SNU Bio Angel. This ... to 30.5 billion KRW (US $27.7M) since its founding ... Eutilex to bolster the development and commercialization of its ...
Breaking Biology Technology:
(Date:11/17/2016)... , Nov. 17, 2016 Global Market Watch: ... Public Biobanks (Disease-Based Banks, Population-Based Banks and Academics) market is ... analysis for Private Biobanks shows the highest Compounded Annual Growth ... region during the analysis period 2014-2020. ... CAGR of 9.95% followed by Europe ...
(Date:11/15/2016)... Research and Markets has announced the addition of the ... their offering. ... The global bioinformatics market ... 6.21 Billion in 2016, growing at a CAGR of 21.1% during ... is driven by the growing demand for nucleic acid and protein ...
(Date:6/22/2016)... -- The American College of Medical Genetics and Genomics was once ... one of the fastest-growing trade shows during the Fastest 50 ... Las Vegas . Winners ... each of the following categories: net square feet of paid ... The 2015 ACMG Annual Meeting was ranked 23 out of ...
Breaking Biology News(10 mins):